SBIR grant awarded to develop treatment for hepatorenal syndrome associated with alcoholic liver disease

0

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and MitoPower LLC (“MitoPower”) have received a Small Business Innovation Research (SBIR) grant of up to $ 6.5 million. dollars over five years from the National Institutes. of the National Institute of Health on alcohol abuse and alcoholism. The funds will support the development of MitoPower’s flagship compound, MP-04, for the treatment of kidney dysfunction due to alcoholic liver disease, a condition known as hepatorenal syndrome associated with alcoholic liver disease (SHR). The IHV, a center of excellence of the Global Virus Network (GVN), will conduct ascending single and multiple dose studies in humans to test the safety of the compound, followed by a phase 1b study in patients.

There are currently no treatment options that specifically address the cellular dysfunction and systemic inflammatory response that contribute to severe impairment of liver and kidney function and progressive organ failure in patients with alcoholic hepatitis. severe. We are working to complete studies enabling IND for MP-04 and are delighted to collaborate with IHV to characterize this promising compound in human studies. “

Mani Subramanian, MD, PhD and CEO of MitoPower

More than 250,000 hospitalizations each year in the United States are due to complications from alcoholic liver disease. SHR is an acute complication of progressive cirrhosis (scarring of the liver) or severe alcoholic hepatitis (inflammation of the liver) leading to kidney failure. SHR is associated with death rates as high as 50%, with many patients requiring invasive treatments such as dialysis and / or liver transplantation.

“There is an urgent and unmet need for effective treatment to treat RHS caused by severe alcoholic hepatitis and cirrhosis. Globally, the incidence and prevalence of alcoholic liver disease continues to increase and remains a major cause of liver failure and liver transplantation, ”said Prof. Shyam Kottilil, MBBS, PhD, Professor of Medicine and Director of the Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, and Senior Advisor to the Global Virus Network (GVN). “MP-04 is a new therapy that has shown promise in preclinical studies for reversing organ dysfunction and systemic inflammatory response syndrome (SIRS) which shows promise for potentially reversing SHR.”

Theodore E. Woodward Stephen N. Davis Chair in Medicine, MBBS, FRCP, FACE, MACP, said, “We are honored to collaborate with academic research with industry to develop therapies that improve the health and quality of life of our patients, especially for chronic diseases. diseases for which we have no known cure.

UMSOM Dean E. Albert Reece, MD, PhD, MBA, Executive Vice President of Medical Affairs, UM Baltimore, and Distinguished Professor John Z. and Akiko K. Bowers, Said: Black Americans and Mexican Americans are more likely to suffer worse results. Developing an effective treatment will be the first step in finding a way to address these disparities. “

Robert Gallo, MD, Homer & Martha Gudelsky Distinguished Professor of Medicine, Co-Founder and Director of the Institute of Human Virology at UMSOM, and Co-Founder and International Scientific Director of the Global Virus Network (GVN), said: “The Institute is pleased to see that the portfolio of our clinical trials unit continues to grow under the formidable leadership of Professor Kottilil. As we continue to focus on therapies for viruses such as HIV and SARS-CoV-2, it is also important that we research innovations that can combat devastating chronic diseases, such as liver disease and heart disease. kidney dysfunctions. “

This award was presented by the National Institutes of Health under number U44 AA029833. The contents of this press release are the sole responsibility of the author and do not necessarily represent the official views of the NIH.


Source link

Leave A Reply

Your email address will not be published.